9 September 2021 in Proceedings of the National Academy of Sciences
Expression and function of odorant receptors (ORs), which account for more than 50% of G protein–coupled receptors, are being increasingly reported in nonolfactory sites. However, ORs that can be targeted by drugs to treat diseases remain poorly identified. Tumor-derived lactate plays a crucial role in multiple signaling pathways leading to generation of tumor-associated macrophages (TAMs). In this study, we hypothesized that the macrophage OR Olfr78 functions as a lactate sensor and shapes the macrophage–tumor axis. Using Olfr78+/+ and Olfr78−/− bone marrow–derived macrophages with or without exogenous Olfr78 expression, we demonstrated that Olfr78 sensed tumor-derived lactate, which was the main factor in tumor-conditioned media responsible for generation of protumoral M2-TAMs. Olfr78 functioned together with Gpr132 to mediate lactate-induced generation of protumoral M2-TAMs. In addition, syngeneic Olfr78-deficient mice exhibited reduced tumor progression and metastasis together with an increased anti- versus protumoral immune cell population. We propose that the Olfr78–lactate interaction is a therapeutic target to reduce and prevent tumor progression and metastasis. Significance Expression and function of odorant receptors (ORs) are being increasingly reported in nonolfactory sites. However, ORs that can be targeted by drugs to treat diseases remain poorly identified. Here, we hypothesized that the macrophage OR Olfr78 functions as a tumor-derived lactate sensor and shapes the macrophage–tumor axis. Olfr78 and the G protein–coupled receptor Gpr132 form a heterodimer that senses lactate in the tumor microenvironment, leading to generation of tumor-associated macrophages with a protumoral M2 phenotype, which promotes tumor progression and metastasis. Our findings suggest an alternative strategy for cancer treatment, namely targeting the interaction between tumor-derived metabolites and ORs.
30 January 2020 in The FEBS Journal
Microglia (MG), the principal neuroimmune sentinels in the brain, continuously sense changes in their environment and respond to invading pathogens, toxins, and cellular debris, thereby affecting neuroinflammation. Microbial pathogens produce small metabolites that influence neuroinflammation, but the molecular mechanisms that determine whether pathogen‐derived small metabolites affect microglial activation of neuroinflammation remain to be elucidated. We hypothesized that odorant receptors (ORs), the largest subfamily of G protein‐coupled receptors, are involved in microglial activation by pathogen‐derived small metabolites. We found that MG express high levels of two mouse ORs, Olfr110 and Olfr111, which recognize a pathogenic metabolite, 2‐pentylfuran, secreted by Streptococcus pneumoniae. These interactions activate MG to engage in chemotaxis, cytokine production, phagocytosis, and reactive oxygen species generation. These effects were mediated through the Gαs–cyclic adenosine monophosphate–protein kinase A–extracellular signal‐regulated kinase and Gβγ–phospholipase C–Ca2+ pathways. Taken together, our results reveal a novel interplay between the pathogen‐derived metabolite and ORs, which has major implications for our understanding of microglial activation by pathogen recognition.Database: Model data are available in the PMDB database under the accession number PM0082389.
31 March 2020 in FEBS Open Bio
Odor adaptation allows the olfactory system to regulate sensitivity to different stimulus intensities, which is essential for preventing saturation of the cell‐transducing machinery and maintaining high sensitivity to persistent and repetitive odor stimuli. Although many studies have investigated the structure and mechanisms of the mammalian olfactory system that responds to chemical sensation, few studies have considered differences in neuronal activation that depend on the manner in which the olfactory system is exposed to odorants, or examined activity patterns of olfactory‐related regions in the brain under different odor exposure conditions. To address these questions, we designed three different odor exposure conditions that mimicked diverse odor environments and analyzed c‐Fos‐expressing cells (c‐Fos+ cells) in the odor columns of the olfactory bulb (OB). We then measured differences in the proportions of c‐Fos‐expressing cell types depending on the odor exposure condition. Surprisingly, under the specific odor condition in which the olfactory system was repeatedly exposed to the odorant for 1 min at 5‐min intervals, one of the lateral odor columns and the ipsilateral hemisphere of the olfactory tubercle had more c‐Fos+ cells than the other three odor columns and the contralateral hemisphere of the olfactory tubercle. However, this interhemispheric asymmetry of c‐Fos expression was not observed in the anterior piriform cortex. To confirm whether the anterior olfactory nucleus pars externa (AONpE), which connects the left and right OB, contributes to this asymmetry, AONpE‐lesioned mice were analyzed under the specific odor exposure condition. Asymmetric c‐Fos expression was not observed in the OB or the olfactory tubercle. These data indicate that the c‐Fos expression patterns of the olfactory‐related regions in the brain are influenced by the odor exposure condition and that asymmetric c‐Fos expression in these regions was observed under a specific odor exposure condition due to synaptic linkage via the AONpE.
30 April 2024 in Annals of Coloproctology
Purpose: Colorectal cancer (CRC) is the most frequent cancer with limited therapeutic achievements. Recently, adoptive cellular immunotherapy has been developed as an antitumor therapy. However, its efficacy has not been tested in CRC. This study investigated the ability of an immune cell cocktail of dendritic cells (DCs), T cells, and natural killer (NK) cells to overcome immunological hurdles and improve the therapeutic efficacy of cell therapy for CRC.Methods: CRC lysate-pulsed monocyte-derived DCs (Mo-DCs), CRC antigen-specifically expanded T cells (CTL), and in vitro-expanded NK cells were cultured from patient peripheral blood mononuclear cells (PBMC). The ability of the combined immune cells to kill autologous tumor cells was investigated by co-culturing the combined immune cells with patient-derived tumor cells.Results: The Mo-DCs produced expressed T cell co-stimulating molecules like CD80, CD86, human leukocyte antigen (HLA)-DR and HLA-ABC, at high levels and were capable of activating naive T cells. The expanded T cells were predominantly CD8 T cells with high levels of CD8 effector memory cells and low levels of regulatory T cells. The NK cells expressed high levels of activating receptors and were capable of killing other cancer cell lines (K562 and HT29). The immune cell cocktail demonstrated a higher ability to kill autologous tumor cells than single types. An in vivo preclinical study confirmed the safety of the combined immune cell adaptive therapy showing no therapy-related death or general toxicity symptoms.Conclusion: The results suggested that combined immune cell adaptive therapy could overcome the limited efficacy of cell immunotherapy.